IFA
OYST

Invus Financial Advisors’s Oyster Point Pharma, Inc. Common Stock OYST Stock Holding History

Invus Financial Advisors’s Portfolio OYST Stock Details OYST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,768,586
Closed -$30.9M – 9
2022
Q4 		$30.9M Hold
2,768,586
– – 16.46% 3
2022
Q3 		$15.6M Hold
2,768,586
– – 8.54% 5
2022
Q2 		$12M Hold
2,768,586
– – 7.24% 6
2022
Q1 		$32.2M Hold
2,768,586
– – 14.34% 4
2021
Q4 		$50.6M Hold
2,768,586
– – 15.36% 4
2021
Q3 		$32.8M Hold
2,768,586
– – 8.79% 5
2021
Q2 		$47.6M Hold
2,768,586
– – 9.48% 5
2021
Q1 		$50.6M Hold
2,768,586
– – 11.6% 3
2020
Q4 		$52.1M Hold
2,768,586
– – 21.78% 2
2020
Q3 		$58.4M Hold
2,768,586
– – 28.12% 1
2020
Q2 		$80M Buy
2,768,586
+178,571
+7% +$5.38M 28.9% 1
2020
Q1 		$90.7M Hold
2,590,015
– – 44.5% 1
2019
Q4 		$63.3M Buy
+2,590,015
New +$45.5M 32.1% 1

Other funds holding OYST

HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Invus Financial Advisors's OYST Position: Q1 2023 in Review

Invus Financial Advisors sold out of Oyster Point Pharma, Inc. Common Stock (OYST) in Q1 2023, closing a stake of 2,768,586 shares — an estimated $30.9M sold.

Invus Financial Advisors first reported a position in OYST in Q4 2019 and held it in 13 quarters. The position peaked at $90.7M in Q1 2020. 1 fund tracked by Wall St. Rank holds OYST as of Q1 2023.

  • Invus Financial Advisors reported no remaining Oyster Point Pharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Invus Financial Advisors sold 2,768,586 Oyster Point Pharma, Inc. Common Stock shares in Q1 2023, an estimated $30.9M.
  • Invus Financial Advisors first reported a position in Oyster Point Pharma, Inc. Common Stock in Q4 2019 and held it in 13 quarters.
  • Invus Financial Advisors's Oyster Point Pharma, Inc. Common Stock position peaked at $90.7M in Q1 2020.
  • 1 fund tracked by Wall St. Rank held Oyster Point Pharma, Inc. Common Stock as of Q1 2023.

Based on Invus Financial Advisors's 13F filing for Q1 2023, filed 15 May 2023.